Accessible Search Form           Advanced Search

Christopher Hourigan, M.D., D.Phil.

Publications


Principal Investigator thumbnail image

Christopher Hourigan
Assistant Clinical Investigator

P: +1 301 451 0257
hourigancs@mail.nih.gov


Full Publications Listing

Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.
Hourigan CS, McCarthy P, de Lima M.
Biol Blood Marrow Transplant. 2014 Feb 1;20(2):154-63.
[Text Abstract on PubMed]

Repair of impaired pulmonary function is possible in very-long-term allogeneic stem cell transplantation survivors.
Jain NA, Pophali PA, Klotz JK, Ito S, Koklanaris E, Chawla K, Hourigan CS, Gormley N, Savani BN, Barrett AJ, Battiwalla M.
Biol Blood Marrow Transplant. 2014 Feb 1;20(2):209-13.
[Text Abstract on PubMed]

Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.
Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, Strickland SA, Jagasia M, Savani BN, Fraser JW, Sadrzadeh H, Rajkhowa T, Ito S, Jain NA, Battiwalla M, Fathi AT, Levis MJ, Barrett AJ, Hourigan CS.
Leukemia. 2014 Jan 1.
[Text Abstract on PubMed]

Contrast enhanced cardiac CT reveals coronary artery disease in 45% of asymptomatic allo-SCT long-term survivors.
Jain NA, Chen MY, Shanbhag S, Lu K, Pophali PA, Ito S, Koklanaris E, Hourigan CS, Barrett AJ, Battiwalla M.
Bone Marrow Transplant. 2013 Nov 18.
[Text Abstract on PubMed]

Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events.
Pophali PA, Klotz JK, Ito S, Jain NA, Koklanaris E, Le RQ, Hourigan CS, Savani BN, Chawla K, Shanbhag S, Barrett AJ, Battiwalla M.
Exp Hematol. 2013 Oct 17.
[Text Abstract on PubMed]

Minimal residual disease in acute myeloid leukaemia.
Hourigan CS, Karp JE.
Nat Rev Clin Oncol. 2013 Jun 25.
[Text Abstract on PubMed]

Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma.
Hourigan CS, Forde PM, Ambinder RF, Gladstone DE.
Leuk Lymphoma. 2013 Apr 19.
[Text Abstract on PubMed]

Personalized therapy for acute myeloid leukemia.
Hourigan CS, Karp JE.
Cancer Discov. 2013 Dec ;3(12):1336-8.
[Text Abstract on PubMed]

Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.
Qin L, Smith BD, Tsai HL, Yaghi NK, Neela PH, Moake M, Fu J, Kasamon YL, Prince GT, Goswami M, Rosner GL, Levitsky HI, Hourigan CS.
Blood Cancer J. 2013 01 ;3:e145.
[Text Abstract on PubMed]

Barrett's, blood groups and progression to oesophageal cancer: is nitric oxide the link?
Caygill CP, Royston C, Charlett A, Wall CM, Gatenby PA, Ramus JR, Watson A, Winslet M, Hourigan CS, Dev Bardhan K.
Eur J Gastroenterol Hepatol. 2011 Sep;23(9):801-6.
[Text Abstract on PubMed]

Evaluation of current cancer immunotherapy: hemato-oncology.
Hourigan CS, Levitsky HI.
Cancer J. 2011 Sep-Oct;17(5):309-24.
[Text Abstract on PubMed]

New considerations in the design of clinical trials for the treatment of acute leukemia.
Hourigan CS, Karp JE.
Clin Investig (Lond). 2011 Apr 1;1(4):509-517.
[Text Abstract on PubMed]

Development of therapeutic agents for older patients with acute myelogenous leukemia.
Hourigan CS, Karp JE.
Curr Opin Investig Drugs. 2010 Jun;11(6):669-77.
[Text Abstract on PubMed]

The structure of the human allo-ligand HLA-B*3501 in complex with a cytochrome p450 peptide: steric hindrance influences TCR allo-recognition.
Hourigan CS, Harkiolaki M, Peterson NA, Bell JI, Jones EY, O'Callaghan CA.
Eur. J. Immunol. 2006 Dec;36(12):3288-93.
[Text Abstract on PubMed]

The molecular basis of coeliac disease.
Hourigan CS.
Clin. Exp. Med. 2006 Jun;6(2):53-9.
[Text Abstract on PubMed]

Are medical schools fit for graduates?
Hourigan CS.
BMJ. 2005 Nov 5;331(7524):1084.
[Text Abstract on PubMed]

Registering organ donor preferences - a third way?
Hourigan CS.
Br J Gen Pract. 2005 Oct;55(519):805.
[Text Abstract on PubMed]

The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain.
Purbhoo MA, Boulter JM, Price DA, Vuidepot AL, Hourigan CS, Dunbar PR, Olson K, Dawson SJ, Phillips RE, Jakobsen BK, Bell JI, Sewell AK.
J. Biol. Chem. 2001 Aug 31;276(35):32786-92.
[Text Abstract on PubMed]

A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex.
Xu XN, Purbhoo MA, Chen N, Mongkolsapaya J, Cox JH, Meier UC, Tafuro S, Dunbar PR, Sewell AK, Hourigan CS, Appay V, Cerundolo V, Burrows SR, McMichael AJ, Screaton GR.
Immunity. 2001 May;14(5):591-602.
[Text Abstract on PubMed]